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Osteopontin is a multifunctional 34kDa extracellular matrix protein with a cell-binding domain. It is involved cell adhesion and cell
migration and is therefore considered to influence tumorigenesis and/or metastasis. The purpose of the present study was to evaluate
the clinical significance of Osteopontin expression in oesophageal squamous cell carcinoma (ESCC). In the present study, we
immunohistochemically investigated the relationship between Osteopontin expression and clinicopathological factors including
prognosis in surgical specimens of primary tumours in 175 patients with ESCC. Osteopontin was expressed in 48% of 175 patients.
Osteopontin expression was significantly correlated with lymph node metastasis, lymphatic invasion, and stage (P¼0.0015, 0.037 and
0.033, respectively). Tumours with expressing Osteopontin exhibited more lymph node metastasis, lymphatic invasion and advanced
stage than the tumour with negative Osteopontin expression. Five-year survival rate was better in patients with negative Osteopontin
expression than in those with positive Osteopontin expression (P¼0.035). However, multivariate analysis revealed that Osteopontin
expression was not an independent prognostic factor. As our findings suggest that Osteopontin may play an important role in
progress of ESCC, the evaluation of Osteopontin expression is useful for predicting the malignant properties of ESCC.
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Osteopontin is a 34kDa extracellular matrix protein with a cell-
binding domain (Sodek et al, 2000) and was originally identified as
a major component of the noncollagenous organic bone matrix. It
secretes adhesive glycoprotein and seems to be involved in
osteoblast differentiation, bone formation and remodelling of
mineralised tissue (Reinholt et al, 1990; Giachelli and Steitz, 2000).
Other molecules which share this domain include fibronectin,
vitronectin and a variety of other extracellular proteins that bind
members of the integrin family of cell surface receptors (Varner
and Cheresh, 1996). The expression of Osteopontin has subse-
quently been demonstrated in a wide range of normal human
tissue and body fluid such as osteoblasts, arterial smooth muscle
cells, leukocytes, activated macrophages and T cells (Coppola et al,
2004), and epithelia of the gastro-intestinal tract (Brown et al,
1992; Brown et al, 1994). It is a multifunctional protein involved in
cell adhesion and cell migration, and has been shown to play
important roles in tumorigenesis, tumour invasion, metastasis and
prognosis among patients with breast (Tuck et al, 1998), lung
(Zhang et al, 2001; Donati et al, 2005), prostate (Thalmann et al,
1999), gastric (Ue et al, 1998) and colon cancer (Agrawal et al,
2002).
Oesophageal squamous cell carcinoma (ESCC) is one of the
most aggressive carcinomas in the gastrointestinal tracts. Studies
of various biological factors affecting the malignant potential of
ESCC have been performed. However, the expression of Osteo-
pontin in ESCC has not been evaluated. The aims of this
retrospective study were to examine the expression of Osteopontin
in surgical specimens of ESCC and to evaluate whether this is
useful in predicting outcome.
MATERIALS AND METHODS
Patients and specimens
Subjects were 175 patients with ESCC (160 men and 15 women)
who underwent oesophagectomy with lymph node dissection
between 1987 and 1998 at Kagoshima University Hospital, Japan.
The median age of the patients was 64 years (range 36–83 years).
None of these patients underwent endoscopic mucosal resection,
palliative resection, preoperative chemotherapy and/or radio-
therapy, and none of them had synchronous or metachronous
cancer in other organs. Specimens of cancer tissues and
noncancerous adjacent tissue were collected from patients after
informed consent had been obtained in accordance with the
institutional guidelines of our hospital. Using the tumour node
metastasis classification of the International Union Against Cancer
(Sobin and Fleming, 1997), all of the M1 tumours exhibited distant
lymph node metastases. Clinicopathologic data of patients in this
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sstudy were shown in Table 1. All patients were followed-up after
discharge, with X-ray examination and tumour marker assays
(squamous cell carcinoma antigen and carcinoembryonic antigen)
every 1–3 months, computed tomography every 3–6 months, and
ultrasonography every 6 months. Bronchoscopy and endoscopy
were performed when necessary. Postoperative follow-up data
were obtained from all patients, with a median follow-up period of
28 months (range, 1–175 months).
Immunohistochemical staining and evaluation
Specimens were cut into 3-mm-thick sections, which were mounted
on glass slides. Immunohistochemical staining was carried out
using the avidin–biotin–peroxidase complex method (Vectastatin
Elite ABC Kit; Vector, Burlingame, CA, USA), following the
manufacturer’s instructions. Briefly, the immunostaining was
performed manually at room temperature. Sections were depar-
affinised in xylene and dehydrated in ethanol, endogenous
peroxidase activity was blocked by incubating sections for
10min in 3% hydrogen peroxide in methanol. Sections then were
then heated using an autoclave in a citrate buffer (0.01moll
 1,p H
6.5) at 1211C for 15min to reveal the antigen. After cooling,
sections were preincubated in 1% borine serum albmin (BSA) for
20min. Next, sections were incubated with antiosteopontin
monoclonal antibody (1:50, Osteopontin, Novocastra Laboratories
Ltd, Newcastle, UK) for 60min. After rinsing with phosphate-
buffered saline (PBS) for 15min, sections were incubated with
secondary antibody for 20min and washed again with PBS for
10min. Sections were incubated with avidin–biotin complex for
30min and washed again, and reactions were visualized using
diaminobenzidine tetrahydrochloride for 2min. All samples were
lightly counterstained with haematoxylin for 1min. The negative
controls consisted of sections treated with PBS instead of primary
antibody. A section of normal tissue of gallbladder was used as
positive control. Evaluation of immunohistochemistry was per-
formed independently by two investigators (KY and SN). Positive
Osteopontin expression was defined as detectable immunoreaction
in perinuclear and other cytoplasmic regions of 410% of the
cancer cells. To evaluate expression of Osteopontin, 10 fields
(within the tumour and at the invasive front) were selected, and
expression in 1000 tumour cells (100 cells/field) was evaluated
using high-power ( 200) microscopy.
Statistical analysis
Statistical analysis of group differences was performed using the w
2
test. The Kaplan–Meier method was used for survival analysis, and
differences in survival were estimated using the log rank test.
Prognostic factors were examined by univariate and multivariate
analyses (Cox proportional hazards regression model). Po0.05
was considered to indicate statistical significance. All statistical
analyses were performed using the StatViewt for Windows
software (Version 5.0, Abacus Concepts, Berkeley, CA, USA).
RESULTS
Expression of Osteopontin in oesophageal squamous cell
carcinoma
Osteopontin was expressed in the cytoplasm of ESCC cells in 48%
(84 of 175) of all patients (Figure 1).
Relationship between Osteopontin and clinicopathologic
variables
Osteopontin expression was significantly associated with the
following clinicopathologic parameters: lymph node metastasis,
stage and lymphatic invasion (Table 1). Patients with positive
Osteopontin expression had more lymph node metastasis and
greater lymphatic invasion than those with negative Osteopontin
expression (P¼0.0015 and 0.037, respectively).
Relationship between Osteopontin expression and
prognosis
The 5-year survival rate was significantly lower in patients with
positive Osteopontin expression than in those with negative
Osteopontin expression (P¼0.035; Figure 2).
Univariate and multivariate analyses of survival
Tables 2 and 3 show univariate and multivariate analyses of factors
related to patient prognosis. Univariate analysis showed that the
Table 1 Relationship between Osteopontin expression and clinico-
pathological findings
Osteopontin
Positive Negative
Total
(n¼175)
n¼84
(48.0%)
n¼91
(52.0%) P-value
Age
Mean 62.8 63.3 0.7041
SD
a 8.0 9.8
Gender
Male 160 80 (87.9) 80 (95.2) 0.0775
Female 15 11 (12.1) 4 (4.8)
Tumour location
Upper 23 15 (16.5) 8 (9.5) 0.1611
Middle 92 50 (55.0) 42 (50.0)
Lower 60 26 (28.5) 34 (40.5)
Histology
Well 62 29 (34.5) 33 (36.3) 0.5678
Moderate 85 39 (46.6) 46 (50.5)
Poor 28 16 (19.1) 12 (13.8)
pT
pT1 58 24 (28.6) 34 (37.4) 0.4339
pT2 22 9 (10.7) 13 (14.3)
pT3 66 35 (41.7) 31 (34.0)
pT4 29 16 (19.0) 13 (14.3)
pN
pN0 78 27 (32.1) 51 (56.0) 0.0015
pN1 97 57 (77.9) 40 (44.0)
pM
pM0 131 57 (67.9) 74 (81.3) 0.1398
pM1 44 27 (32.1) 17 (18.7)
Stage
I 41 14 (16.7) 27 (29.7) 0.0333
IIA 31 12 (14.2) 19 (20.9)
IIB 21 14 (16.7) 7 (7.7)
III 38 17 (20.2) 21 (23.1)
IV 44 27 (32.2) 17 (18.6)
Lymphatic invasion
Negative 66 25 (29.8) 41 (45.1) 0.0375
Positive 109 59 (70.2) 50 (54.9)
Venous invasion
Negative 125 52 (61.9) 66 (72.5) 0.1339
Positive 50 32 (38.1) 25 (27.5)
aStandard deviation.
Osteopontin in ESCC
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sfollowing factors were significantly related to postoperative
survival: depth of invasion and lymph node metastasis, stage,
lymphatic invasion, venous invasion and Osteopontin expression
(Po0.05). Multivariate regression analysis indicated that depth of
invasion, lymph node metastasis and venous invasion were
independent prognostic factors, but that lymphatic invasion and
Osteopontin expression were not independent prognostic factors.
DISCUSSION
In this study, we immunohistochemically investigated the relation-
ship between Osteopontin expression and clinicopathological
factors, including prognosis, in ESCC. The expression of
Osteopontin was observed in 48% of tumours. This was consistent
with previous immunohistochemical studies on other carcinomas
in which Osteopontin expression was detected in 33.3–70.0% (Ue
et al, 1998; Zhang et al, 2001; Coppola et al, 2004).
In the present study, Osteopontin expression was significantly
associated with lymph node metastasis and lymphatic invasion. In
non-small cell lung cancer, the expression of Osteopontin in
surgical specimens is significantly correlated with tumour size,
lymph node metastasis and stage (Donati et al, 2005). In the ESCC,
plasma Osteopontin was associated with lymph node metastasis
(Shimada et al, 2005). In gastric cancer, the expression of
Osteopontin in poorly differentiated tumours is also associated
with lymphogenous metastasis (Ue et al, 1998). Taking these
results together, it appears that the expression of Osteopontin in
some human malignant tumours might be more associated with
metastasis than with tumorigenesis.
The molecular mechanisms that define the role of Osteopontin
in tumour metastasis have not been completely elucidated,
although several mechanisms have been suggested. Previous
studies showed that Osteopontin can support attachment for a
variety of cell types and promote migration of tumour cells (Oates
et al, 1997; Tuck et al, 2000). Osteopontin contains the cell
Figure 1 Expression of Osteopontin in ESCCs. (A) positive expression of Osteopontin was detectable in cytoplasmic regions ( 100); (B) magnified
view ( 400) (C) negative expression of Osteopontin ( 100). (D) magnified view ( 400).
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Figure 2 The postoperative 5-years survival curves between the patients
expression ( ) and expression (þ) with Osteopontin. There was a
significant difference between the patients with Osteopontin ( ) and (þ)
expression (P¼0.0354).
Osteopontin in ESCC
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acid), which bind to the alpha vs beta 3 integrin heterodimer, play
a role in cell adhesion (Xuan et al, 1995). In addition, Osteopontin
bind several different cellular receptors, potentially allowing it to
stimulate various signalling pathways and influence cellular events
that may ultimately promote tumorgenesis, adhesion, migration
and metastasis (Hu et al, 1995; Liaw et al, 1995; Weber et al, 1996;
Al-Shami et al, 2005). The down-stream Osteopontin signals which
interrupt the cell cycle, prevent apoptosis and promote cell
survival are integral to tumour progression (Evan and Vousden,
2001). There may be especially signals that corresponded with
lymph node metastasis in those signals that Osteopontin stimulate.
In the present study, close relationship was found between
Osteopontin expression and lymph node metastasis.
Concerning the survival analysis, sex, tumour depth, lymph
node metastasis, stage, lymphatic invasion, venous invasion and
Osteopontin expression were prognostic factors on univariate
analysis. However, multivariate analysis revealed that only tumour
depth, nodal metastasis and venous invasion were independent
prognostic factors. It has previously been demonstrated that
plasma Osteopontin in ESCC is associated with poor survival
(Shimada et al, 2005). Expression of Osteopontin is also
significantly associated with poor survival in stage I non-small
cell lung cancer (Donati et al, 2005). These findings indicate that
the Osteopontin overexpression in some tumours is correlated
with poor prognosis, predominantly via lymph node metastasis.
Although Osteopontin expression in ESCC was not found to be an
independent prognostic factor in the present study, it might play
an important role in promoting progression and migration to the
lymphatic system. Thus, evaluation of Osteopontin expression
using biopsy specimens before surgical therapy may be a new
standard for appropriate lymph node dissection of ESCC.
In conclusion, we detected Osteopontin protein in ESCC and
found this to be associated with lymph node metastasis, stage,
lymphatic invasion, and prognosis. Osteopontin is therefore useful
for predicting malignant properties. These findings suggested a
possible role for Osteopontin expression level as a new diagnostic
and prognostic biomarker for ESCC. Furthermore, understanding
the biological function of Osteopontin expression in ESCC may
help to determine its role in physiology of ESCC.
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